Your browser doesn't support javascript.
loading
Major Adverse Kidney Events in Pediatric Continuous Kidney Replacement Therapy.
Fuhrman, Dana Y; Stenson, Erin K; Alhamoud, Issa; Alobaidi, Rashid; Bottari, Gabriella; Fernandez, Sarah; Guzzi, Francesco; Haga, Taiki; Kaddourah, Ahmad; Marinari, Eleonora; Mohamed, Tahagod H; Morgan, Catherine J; Mottes, Theresa; Neumayr, Tara M; Ollberding, Nicholas J; Raggi, Valeria; Ricci, Zaccaria; See, Emily; Stanski, Natalja L; Zang, Huaiyu; Zangla, Emily; Gist, Katja M.
Afiliación
  • Fuhrman DY; University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
  • Stenson EK; Children's Hospital Colorado, University of Colorado School of Medicine, Aurora.
  • Alhamoud I; University of Iowa Stead Family Children's Hospital, Carver College of Medicine, Iowa City.
  • Alobaidi R; University of Alberta, Edmonton, Canada.
  • Bottari G; Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Fernandez S; Gregorio Marañón University Hospital, School of Medicine, Madrid, Spain.
  • Guzzi F; Santo Stefano Hospital, Prato, Italy.
  • Haga T; Osaka City General Hospital, Osaka, Japan.
  • Kaddourah A; Sidra Medicine, Doha, Qatar.
  • Marinari E; Weill Cornell Medical College, Ar-Rayyan, Qatar.
  • Mohamed TH; Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Morgan CJ; Nationwide Children's Hospital, The Heart Center, The Ohio State University College of Medicine, Columbus.
  • Mottes T; University of Alberta, Edmonton, Alberta, Canada.
  • Neumayr TM; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
  • Ollberding NJ; Washington University School of Medicine, St Louis Children's Hospital, St Louis, Missouri.
  • Raggi V; Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Ricci Z; Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • See E; Meyer Children's Hospital, IRCCS, Florence, Italy.
  • Stanski NL; Royal Children's Hospital, University of Melbourne, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Zang H; Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Zangla E; Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Gist KM; University of Minnesota, Minneapolis.
JAMA Netw Open ; 7(2): e240243, 2024 Feb 05.
Article en En | MEDLINE | ID: mdl-38393726
ABSTRACT
Importance Continuous kidney replacement therapy (CKRT) is increasingly used in youths with critical illness, but little is known about longer-term outcomes, such as persistent kidney dysfunction, continued need for dialysis, or death.

Objective:

To characterize the incidence and risk factors, including liberation patterns, associated with major adverse kidney events 90 days after CKRT initiation (MAKE-90) in children, adolescents, and young adults. Design, Setting, and

Participants:

This international, multicenter cohort study was conducted among patients aged 0 to 25 years from The Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) registry treated with CKRT for acute kidney injury or fluid overload from 2015 to 2021. Exclusion criteria were dialysis dependence, concurrent extracorporeal membrane oxygenation use, or receipt of CKRT for a different indication. Data were analyzed from May 2 to December 14, 2023. Exposure Patient clinical characteristics and CKRT parameters were assessed. CKRT liberation was classified as successful, reinstituted, or not attempted. Successful liberation was defined as the first attempt at CKRT liberation resulting in 72 hours or more without return to dialysis within 28 days of CKRT initiation. Main Outcomes and

Measures:

MAKE-90, including death or persistent kidney dysfunction (dialysis dependence or ≥25% decline in estimated glomerular filtration rate from baseline), were assessed.

Results:

Among 969 patients treated with CKRT (529 males [54.6%]; median [IQR] age, 8.8 [1.7-15.0] years), 630 patients (65.0%) developed MAKE-90. On multivariable analysis, cardiac comorbidity (adjusted odds ratio [aOR], 1.60; 95% CI, 1.08-2.37), longer duration of intensive care unit admission before CKRT initiation (aOR for 6 days vs 1 day, 1.07; 95% CI, 1.02-1.13), and liberation pattern were associated with MAKE-90. In this analysis, patients who successfully liberated from CKRT within 28 days had lower odds of MAKE-90 compared with patients in whom liberation was attempted and failed (aOR, 0.32; 95% CI, 0.22-0.48) and patients without a liberation attempt (aOR, 0.02; 95% CI, 0.01-0.04). Conclusions and Relevance In this study, MAKE-90 occurred in almost two-thirds of the population and patient-level risk factors associated with MAKE-90 included cardiac comorbidity, time to CKRT initiation, and liberation patterns. These findings highlight the high incidence of adverse outcomes in this population and suggest that future prospective studies are needed to better understand liberation patterns and practices.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diálisis Renal / Lesión Renal Aguda Límite: Adolescent / Child / Humans / Male Idioma: En Revista: JAMA Netw Open Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diálisis Renal / Lesión Renal Aguda Límite: Adolescent / Child / Humans / Male Idioma: En Revista: JAMA Netw Open Año: 2024 Tipo del documento: Article